Clinical and molecular characteristics according to CXXC5 expression in AML in the HOVON/SAKK cohort
| Characteristic . | CXXC5 lower (n = 264) . | CXXC5 higher (n = 265) . | P . |
|---|---|---|---|
| Age, y | .64 | ||
| Median | 46 | 47 | |
| Range | 15-77 | 15-77 | |
| Sex, % | |||
| Male | 50 | 50 | 1.0 |
| WBC, ×109/L | .89 | ||
| Median | 28 | 29 | |
| Range | 0.3-510 | 0.8-274 | |
| Cytogenetics, %* | |||
| t(8;21); RUNX1-RUNX1T1 | 13 | 2 | <.001 |
| inv(16) or t(16;16); CBFB-MYH11 | 10 | 6 | .15 |
| 11q23 | 9 | 4 | .03 |
| t(6;9); DEK-NUP214 | 1 | 1 | 1.0 |
| inv(3) or t(3;3); RPN1-EVI1 | 1 | 3 | .14 |
| del(5q) | 1 | 1 | .68 |
| Other adverse | 9 | 12 | .57 |
| Normal karyotype | 37 | 48 | .02 |
| Molecular genetics, %† | |||
| FLT3-ITD | 22 | 32 | .01 |
| NPM1 mutated | 30 | 31 | .92 |
| Characteristic . | CXXC5 lower (n = 264) . | CXXC5 higher (n = 265) . | P . |
|---|---|---|---|
| Age, y | .64 | ||
| Median | 46 | 47 | |
| Range | 15-77 | 15-77 | |
| Sex, % | |||
| Male | 50 | 50 | 1.0 |
| WBC, ×109/L | .89 | ||
| Median | 28 | 29 | |
| Range | 0.3-510 | 0.8-274 | |
| Cytogenetics, %* | |||
| t(8;21); RUNX1-RUNX1T1 | 13 | 2 | <.001 |
| inv(16) or t(16;16); CBFB-MYH11 | 10 | 6 | .15 |
| 11q23 | 9 | 4 | .03 |
| t(6;9); DEK-NUP214 | 1 | 1 | 1.0 |
| inv(3) or t(3;3); RPN1-EVI1 | 1 | 3 | .14 |
| del(5q) | 1 | 1 | .68 |
| Other adverse | 9 | 12 | .57 |
| Normal karyotype | 37 | 48 | .02 |
| Molecular genetics, %† | |||
| FLT3-ITD | 22 | 32 | .01 |
| NPM1 mutated | 30 | 31 | .92 |